Clinical Trials
27 trialsNCT00210171 2025-09-10
BIB 01
Institut Bergonié
Phase 2 Withdrawn
NCT01125449 2025-05-18
Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease
Situs Cancer Research Center
Phase 2 Withdrawn
NCT01345084 2025-03-28
NICAP
Eurofarma Laboratorios S.A.
Phase 3 Withdrawn
NCT06365918 2025-02-17
Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With Carcinomatosis
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT04791228 2025-01-01
A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors
Children's National Research Institute
Phase 2 Withdrawn
NCT06084845 2024-07-25
Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer
Eastern Cooperative Oncology Group
Phase 2 Withdrawn
NCT04140513 2024-03-08
Digital PET Scan for the Prediction of Outcomes in Patients With Locally Advanced Oropharyngeal Cancer
Ohio State University Comprehensive Cancer Center
Phase NA Withdrawn
NCT05375825 2024-02-02
Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin
National Institutes of Health Clinical Center (CC)
Phase 1 Withdrawn
NCT04151563 2023-12-19
CheckMate 79X
Bristol-Myers Squibb
Phase 1/2 Withdrawn
NCT05359692 2023-09-15
INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Incyte Corporation
Phase 2 Withdrawn
NCT05512767 2023-01-06
A Pneumatic Compression Device for the Treatment of Lymphedema in Patients With Stage II-IV Head and Neck Cancer After Chemoradiation
Mayo Clinic
Phase NA Withdrawn
NCT04985825 2022-09-13
I-PACE
Centessa Pharmaceuticals plc
Phase 2 Withdrawn
NCT01967927 2021-08-19
Understanding GRID Radiation Therapy Effects on Human Tumor Oxygenation and Interstitial Pressure to Increase Translation of Solid Tumor Therapy
University of Arkansas
Phase EARLY_PHASE1 Withdrawn
NCT04225299 2020-11-13
Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer
Steba Biotech S.A.
Phase 3 Withdrawn
NCT04006691 2020-05-07
Retreatment
UroGen Pharma Ltd.
Phase 3 Withdrawn
NCT02624999 2020-01-22
Study Comparing AlloVaxâ„¢ to Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head & Neck
Mirror Biologics, Inc.
Phase 2 Withdrawn
NCT02851693 2019-04-04
OCTSKIN
Centre Hospitalier Universitaire de Saint Etienne
Phase NA Withdrawn
NCT03717038 2019-02-04
Sym004 Versus TAS-102 in Patients With mCRC
Symphogen A/S
Phase 3 Withdrawn
NCT03240393 2018-07-26
Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)
Novartis
Phase 2 Withdrawn
NCT02298595 2017-11-13
Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma
University of Pittsburgh
Phase 1/2 Withdrawn
NCT02211027 2017-09-07
Biological Vaccine: Semi-allogeneic Human Fibroblasts (MRC-5) Transfected With DNA
University of Pittsburgh
Phase 1 Withdrawn
NCT00386516 2017-08-01
Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer
Galectin Therapeutics Inc.
Phase 2 Withdrawn
NCT01467635 2016-07-13
EBUS-TBNA Versus EBUS-TBNB
Royal Brompton & Harefield NHS Foundation Trust
Phase NA Withdrawn
NCT01799499 2015-09-01
NMIBC TURBT HG
UroGen Pharma Ltd.
Phase NA Withdrawn
NCT00176280 2015-06-18
Randomized Phase 2 Trial of Pre-chemotherapy Leukine vs. Leukine-Dexamethasone in Combination With Gemzar & 5-FU in Patients With Metastatic Renal Cell Carcinoma
University of Kentucky
Phase 2 Withdrawn
NCT02017678 2014-09-17
Phase 2 Study of JX-594 in Patients With Peritoneal Carcinomatosis of Ovarian Cancer Origin
Mount Sinai Hospital, Canada
Phase 2 Withdrawn
NCT01301612 2014-07-14
Study of Nimotuzumab, Radiation Therapy and Cisplatin Versus Radiation Therapy and Cisplatin for Treatment of Stage IB e IVA UCC(CORUS)
Eurofarma Laboratorios S.A.
Phase 2 Withdrawn